- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03788590
Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System (TAVI)
A Prospective, Multicenter, Single-armed Trial That Aims to Evaluate the Safety and Efficacy of Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aortic valve diseases is usually caused by rheumatic fever, congenital aortic valve structural abnormality or degenerative aortic valve calcification. Transcatheter aortic valve implantation (TAVI) has evolved as an alternative to surgical aortic valve replacement (SAVR) with now more than 50,000 implantations in patients with symptomatic severe aortic stenosis, who were considered to be at very high or prohibitive operative risk.
This project take the incidence of all-cause mortality at 12 months since TAVI as the primary endpoint to evaluate the safety and efficacy, then take the procedure success rate, device success rate, incidence of severe adverse events, device operative performance, prosthetic valve performance and quality of life to evaluate transcatheter artificial aortic valve and transcatheter artificial heart values delivery system of Ningbo Jenscare Biotechnology Co., Ltd. in clinical application.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects ≥ 65 years of age;
- Severe aortic stenosis, as defined by ultrasonic cardiogram (peak velocity ≥4.0 m/s, or mean transaortic systolic pressure gradient ≥40 mmHg, or an aortic valve area of <1.0 cm2) or combined merger; severe aortic insufficiency (regurgitation ≥+++ or regurgitation area ≥0.3cm2) combined with left ventricular dilatation ( LVESD≥50mm or LVEDD≥65mm);or severe aortic valve insufficiency combined with left ventricular systolic dysfunction (LVEF<50%);
- Symptoms suggestive of aortic stenosis, NYHA class III or IV;
- Patients who are considered unsuitable for surgery are considered by two or more than two cardiovascular specialists (≥6% using Society of Thoracic Surgeons scoring system estimation; or there is a severe and irreversible organ damage to the patient, such as lung disease, liver disease, kidney disease and so on; or the patient's physical weakness can not be tolerated by surgery; or have other factors affecting surgery, such as postoperative chest radiosurgery, thoracic deformity, and diffuse severe calcification of the aorta, etc);
- A life expectancy of > 1 year;
- Voluntarily participate in and sign the informed consent form and willing to undergo the related examination and clinical follow-up.
Exclusion Criteria:
- Untreated severe coronary stenosis and needs revascularization; or acute myocardial infarction occurred within 1 months, or coronary stent implantation in 1 month;
- Artificial heart valve and artificial valve ring have been implanted;
- Severe mitral insufficiency (regurgitation ≥+++) or mitral stenosis (valvular area<1.5 cm2);
- left ventricular or atrial thrombus;
- Aortic annulus diameter <17mm or >27 mm;
- Severe left ventricular dysfunction, ejection fraction <20%;
- Severe pulmonary hypertension or severe right ventricular dysfunction;
- The ascending aortic ≥5cm or Aortic root diameter ≥4.5cm;
- Cerebrovascular event in last 3 months;
- Active endocarditis or other active infection;
- Severe renal failure and requires long-term dialysis treatment;
- Severe liver dysfunction;
- Active peptic ulcer;
- Severe coagulation dysfunction; it is known that all anticoagulant schemes are taboo or allergic, or anticoagulants can not be used in the process of testing;
- Severe respiratory failure;
- Severe Alzheimer's disease;
- Patients who were enrolled in any other study in one month;
- Other cases which the researchers believe that it is not suitable to participate in.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Jenscare TAVI
Patients undergoing a Jenscare TAVI and delivery system
|
Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better.
It may also shorten your recovery time to getting back to everyday activities.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 12 month
|
Cumulative incidence of a combination of all cause death at 12 month after TAVI
|
12 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure success rate
Time Frame: During the TAVI procedure
|
Documentation of no death occurred during or within 72 hours after TAVI, no conversion to conventional cardiopulmonary bypass, the value was placed in the correct anatomical position and achieve the desired effect
|
During the TAVI procedure
|
Device success rate
Time Frame: During the TAVI procedure
|
Documentation of the device was implanted successfully, placed in the correct anatomical position and achieve the desired effect
|
During the TAVI procedure
|
Incidence of severe adverse events
Time Frame: During the TAVI procedure and 3 days,7 days, 30 days, 3 months, 6 months, 12 months after TAVI
|
Documentation of the serious long-term complications, including mortality, stroke, transient ischemic stroke, myocardial infarction, dialysis and reinterventions
|
During the TAVI procedure and 3 days,7 days, 30 days, 3 months, 6 months, 12 months after TAVI
|
Assessment of device operative performance
Time Frame: During the TAVI procedure
|
Using the following measure (loading and releasing properties of artificial aortic valve; pushing, emptying, withdrawing, developing performance, fracture of the delivery system) that can be converted to utilities using an algorithm.
Utilities range from 1 to 3, with 3 representing perfect performance, and 1 corresponding to the worst performance state.
|
During the TAVI procedure
|
Echocardiographic assessment of valve performance
Time Frame: 30 days, 3 months, 6 months, 12 months after TAVI
|
Using the following measures: effective orifice area (EOA)
|
30 days, 3 months, 6 months, 12 months after TAVI
|
Echocardiographic assessment of valve performance
Time Frame: 30 days, 3 months, 6 months, 12 months after TAVI
|
Using the following measures: transvalvular mean gradient
|
30 days, 3 months, 6 months, 12 months after TAVI
|
Evaluation and improvement of quality of life
Time Frame: Preoperative and 30 days, 3 months, 6 months, 12 months after TAVI
|
Measures 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that can be converted to utilities using an algorithm.
Utilities range from 0 to 1, with 1 representing perfect health, and 0 corresponding to the worst imaginable health state.
|
Preoperative and 30 days, 3 months, 6 months, 12 months after TAVI
|
Echocardiographic assessment of valve performance
Time Frame: 30 days, 3 months, 6 months, 12 months after TAVI
|
Using the following measures: peak flow velocity
|
30 days, 3 months, 6 months, 12 months after TAVI
|
Echocardiographic assessment of valve performance
Time Frame: 30 days, 3 months, 6 months, 12 months after TAVI
|
Using the following measures: degree of aortic valve regurgitation
|
30 days, 3 months, 6 months, 12 months after TAVI
|
Echocardiographic assessment of valve performance
Time Frame: 30 days, 3 months, 6 months, 12 months after TAVI
|
Using the following measures: degree of perivalvular leakage
|
30 days, 3 months, 6 months, 12 months after TAVI
|
Collaborators and Investigators
Investigators
- Study Director: Peng Cao, Doctor, Ningbo Jenscare Biotechnology Co., Ltd.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LT-2017-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Regurgitation
-
Imperial College LondonAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)UnknownHeart Valve Diseases | Aortic Valve Insufficiency | Paravalvular Aortic Regurgitation | Regurgitation, AorticNetherlands
-
Centre Chirurgical Marie LannelongueCompletedCardiac Catheterization | Cardiac Valve Disease | Paravalvular Aortic Regurgitation | Paravalvular Mitral Regurgitation
-
Na Homolce HospitalCentre of Cardiovascular and Transplantation Surgery, Czech Republic; St. Anne... and other collaboratorsRecruitingAortic Valve RegurgitationSerbia, Czechia, Belgium
-
Abbott Medical DevicesEnrolling by invitationParavalvular Aortic RegurgitationUnited States, Spain, Netherlands, Canada, Italy, Poland, United Kingdom
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaTerminatedAortic Regurgitation | Aortic Valve Insufficiency | Regurgitation, Aortic Valve | Aortic Valve | Aortic IncompetenceKorea, Republic of
-
Assistance Publique - Hôpitaux de ParisUnknownPure Aortic RegurgitationFrance
-
Genesis Medtech CorporationRecruiting
-
Centre Chirurgical Marie LannelongueEasy-CRFRecruitingQuality of Life | Cardiac Valve Disease | Outcomes | Paravalvular Aortic Regurgitation | Paravalvular Mitral Regurgitation | Paravalvular LeakBelgium, France, Poland, United Kingdom, Czechia, Greece, Italy, Latvia, Lithuania, Mexico, Spain, Turkey
-
UMC UtrechtTerminatedPeriprosthetic Aortic Valve Regurgitation After TAVINetherlands
-
Michele De BonisCompletedAortic Regurgitation | Functional Mitral RegurgitationItaly
Clinical Trials on Jenscare TAVI
-
University of ZurichRecruitingCoronary Artery Disease | Aortic Stenosis | PCI | TAVISwitzerland
-
University Hospital, BonnCompletedAortic Stenosis | Left Ventricular Function Systolic Dysfunction | High-risk Patients | Transcatheter Aortic Valve ImplantationGermany
-
Sheba Medical CenterCompleted
-
University Hospital, MontpellierEdwards LifesciencesCompletedAortic Valve StenosisFrance
-
German Heart InstituteCharite University, Berlin, GermanyUnknownAortic Valve StenosisGermany
-
Institut für Pharmakologie und Präventive MedizinCompletedAortic Valve StenosisCanada, Italy, Netherlands
-
Azienda Usl di BolognaUniversità degli Studi di Ferrara; University Hospital of Ferrara; Azienda Unità...RecruitingAortic Stenosis, SevereItaly
-
AZ Sint-Jan AVRecruitingAortic Valve StenosisBelgium
-
Opsens, Inc.CompletedSevere Aortic StenosisSpain
-
Royal Sussex County HospitalNational Institute for Cardiovascular Outcomes ResearchUnknown